7-Hydroxy-PIPAT maleateD3 agonist (D3 > D2) CAS# 200722-46-9 |
- Rhoifolin
Catalog No.:BCN1112
CAS No.:17306-46-6
- Dipsacoside B
Catalog No.:BCN5940
CAS No.:33289-85-9
- Nodakenin
Catalog No.:BCN2378
CAS No.:495-31-8
- Neomangiferin
Catalog No.:BCN4970
CAS No.:64809-67-2
- Praeruptorin B
Catalog No.:BCN4988
CAS No.:81740-07-0
- Notopterol
Catalog No.:BCN5386
CAS No.:88206-46-6
Quality Control & MSDS
Number of papers citing our products
Chemical structure
3D structure
Cas No. | 200722-46-9 | SDF | Download SDF |
PubChem ID | 24978534 | Appearance | Powder |
Formula | C20H26INO5 | M.Wt | 487.33 |
Type of Compound | N/A | Storage | Desiccate at -20°C |
Synonyms | 7-OH-PIPAT | ||
Solubility | Soluble to 50 mM in DMSO | ||
Chemical Name | (Z)-but-2-enedioic acid;7-[[(E)-3-iodoprop-2-enyl]-propylamino]-5,6,7,8-tetrahydronaphthalen-2-ol | ||
SMILES | CCCN(CC=CI)C1CCC2=C(C1)C=C(C=C2)O.C(=CC(=O)O)C(=O)O | ||
Standard InChIKey | IQRDHLSQXOATHD-HBRCEPSSSA-N | ||
Standard InChI | InChI=1S/C16H22INO.C4H4O4/c1-2-9-18(10-3-8-17)15-6-4-13-5-7-16(19)12-14(13)11-15;5-3(6)1-2-4(7)8/h3,5,7-8,12,15,19H,2,4,6,9-11H2,1H3;1-2H,(H,5,6)(H,7,8)/b8-3+;2-1- | ||
General tips | For obtaining a higher solubility , please warm the tube at 37 ℃ and shake it in the ultrasonic bath for a while.Stock solution can be stored below -20℃ for several months. We recommend that you prepare and use the solution on the same day. However, if the test schedule requires, the stock solutions can be prepared in advance, and the stock solution must be sealed and stored below -20℃. In general, the stock solution can be kept for several months. Before use, we recommend that you leave the vial at room temperature for at least an hour before opening it. |
||
About Packaging | 1. The packaging of the product may be reversed during transportation, cause the high purity compounds to adhere to the neck or cap of the vial.Take the vail out of its packaging and shake gently until the compounds fall to the bottom of the vial. 2. For liquid products, please centrifuge at 500xg to gather the liquid to the bottom of the vial. 3. Try to avoid loss or contamination during the experiment. |
||
Shipping Condition | Packaging according to customer requirements(5mg, 10mg, 20mg and more). Ship via FedEx, DHL, UPS, EMS or other couriers with RT, or blue ice upon request. |
Description | This ligand has uniquely high affinity and selectivity for the D3 receptor. 8-Hydroxy-PIPAT maleate also available. |
7-Hydroxy-PIPAT maleate Dilution Calculator
7-Hydroxy-PIPAT maleate Molarity Calculator
1 mg | 5 mg | 10 mg | 20 mg | 25 mg | |
1 mM | 2.052 mL | 10.26 mL | 20.52 mL | 41.04 mL | 51.2999 mL |
5 mM | 0.4104 mL | 2.052 mL | 4.104 mL | 8.208 mL | 10.26 mL |
10 mM | 0.2052 mL | 1.026 mL | 2.052 mL | 4.104 mL | 5.13 mL |
50 mM | 0.041 mL | 0.2052 mL | 0.4104 mL | 0.8208 mL | 1.026 mL |
100 mM | 0.0205 mL | 0.1026 mL | 0.2052 mL | 0.4104 mL | 0.513 mL |
* Note: If you are in the process of experiment, it's necessary to make the dilution ratios of the samples. The dilution data above is only for reference. Normally, it's can get a better solubility within lower of Concentrations. |
Calcutta University
University of Minnesota
University of Maryland School of Medicine
University of Illinois at Chicago
The Ohio State University
University of Zurich
Harvard University
Colorado State University
Auburn University
Yale University
Worcester Polytechnic Institute
Washington State University
Stanford University
University of Leipzig
Universidade da Beira Interior
The Institute of Cancer Research
Heidelberg University
University of Amsterdam
University of Auckland
TsingHua University
The University of Michigan
Miami University
DRURY University
Jilin University
Fudan University
Wuhan University
Sun Yat-sen University
Universite de Paris
Deemed University
Auckland University
The University of Tokyo
Korea University
- (-)-Phyllocladene
Catalog No.:BCN7661
CAS No.:20070-61-5
- Piplartine
Catalog No.:BCN4037
CAS No.:20069-09-4
- Hennadiol
Catalog No.:BCN4679
CAS No.:20065-99-0
- Fmoc-D-Gln(Trt)-OH
Catalog No.:BCC3488
CAS No.:200623-62-7
- Fmoc-D-Gln-OPfp
Catalog No.:BCC3487
CAS No.:200622-33-9
- Fmoc-N-Me-Glu(OtBu)-OH
Catalog No.:BCC3213
CAS No.:200616-40-6
- Fmoc-D-Glu(OtBu)-OPfp
Catalog No.:BCC3497
CAS No.:200616-21-3
- Hotrienol
Catalog No.:BCN6340
CAS No.:20053-88-7
- GMX1778 (CHS828)
Catalog No.:BCC6527
CAS No.:200484-11-3
- Picralinal
Catalog No.:BCN4878
CAS No.:20045-06-1
- UB 165 fumarate
Catalog No.:BCC5746
CAS No.:200432-86-6
- 6-Chloroguanine riboside
Catalog No.:BCC8771
CAS No.:2004-07-1
- 16-Nor-15-oxodehydroabietic acid
Catalog No.:BCN3943
CAS No.:200813-31-6
- Pseudoneolinderane
Catalog No.:BCN8034
CAS No.:20082-45-5
- Epicurzerenone
Catalog No.:BCN3521
CAS No.:20085-85-2
- Diosbulbin B
Catalog No.:BCN4879
CAS No.:20086-06-0
- Diosbulbin C
Catalog No.:BCN4880
CAS No.:20086-07-1
- Epinodosin
Catalog No.:BCN3282
CAS No.:20086-60-6
- Xanthotoxol
Catalog No.:BCN4881
CAS No.:2009-24-7
- (D)-(+)-Neopterin
Catalog No.:BCC7960
CAS No.:2009-64-5
- m-3M3FBS
Catalog No.:BCC7209
CAS No.:200933-14-8
- SB 243213 dihydrochloride
Catalog No.:BCC6035
CAS No.:200940-23-4
- Ac-RYYRWK-NH2
Catalog No.:BCC5755
CAS No.:200959-47-3
- Ac-RYYRIK-NH2
Catalog No.:BCC5736
CAS No.:200959-48-4
Entecavir maleate versus entecavir in Chinese chronic hepatitis B predominantly genotype B or C: Results at week 144.[Pubmed:28345157]
J Viral Hepat. 2017 Oct;24(10):877-884.
Reports on the efficacy and safety of long-term entecavir treatment in chronic hepatitis B (CHB) predominantly genotype B or C are insufficient. This study presents the efficacy and safety of entecavir maleate in Chinese CHB patients. Patients were randomly assigned to receive 48-week treatment with either 0.5 mg/day entecavir (group A) or 0.5 mg/day entecavir maleate (group B), and then all patients received treatment with 0.5 mg/day entecavir maleate from week 49. Two hundred and seventy-five patients with CHB (HBeAg-positive: 218) were analysed, predominantly (98.5%) with genotype B or C. Baseline characteristics were balanced. For the HBeAg-positive CHB patients, the mean HBV DNA level decreased similarly (A: by 6.36 log10 IU/mL vs B: by 6.31 log10 IU/mL) between groups at week 144. The percentages of patients who achieved undetectable HBV DNA were similar (A: 70.59% vs B: 66.67%) between groups. Similar HBeAg loss rates (A: 43.53% vs B: 40.23%; P>.05) and HBeAg seroconversion rates (A: 21.52% vs B: 21.18%) were achieved. For the HBeAg-negative CHB patients, similar reductions in HBV DNA levels from baseline (A: by 6.13 log10 IU/mL vs B: by 5.65 log10 IU/mL) and percentages of patients who achieved undetectable HBV DNA (A: 100% vs B: 100%) were achieved. The overall incidence of adverse events was comparable between groups. In conclusions, 48-week administration of entecavir maleate and entecavir showed similar efficacy and safety in Chinese patients with CHB. Long-term entecavir maleate treatment was effective and safe in CHB patients.
Determination of fluvoxamine maleate in human urine and human serum using alkaline KMnO4 -rhodamine B chemiluminescence.[Pubmed:28371383]
Luminescence. 2017 Sep;32(6):1077-1083.
The flow-injection chemiluminescence (FI-CL) behavior of a gold nanocluster (Au NC)-enhanced rhodamine B-KMnO4 system was studied under alkaline conditions for the first time. In the present study, the as-prepared bovine serum albumin-stabilized Au NCs showed excellent stability and reproducibility. The addition of trace levels of fluvoxamine maleate (Flu) led to an obvious decline in CL intensity in the rhodamine B-KMnO4 -Au NCs system, which could be used for quantitative detection of Flu. Under optimized conditions, the proposed CL system exhibited a favorable analytical performance for Flu determination in the range 2 to 100 mug ml(-1) . The detection limit for Flu measurement was 0.021 mug ml(-1) . Moreover, this newly developed system revealed outstanding selectivity for Flu detection when compared with a multitude of other species, such as the usual ions, uric acid and a section of hydroxy compounds. Additionally, CL spectra, UV-visible spectroscopes and fluorescence spectra were measured in order to determine the possible reaction mechanism. This approach could be used to detect Flu in human urine and human serum samples with the desired recoveries and could have promising application under physiological conditions.
[Chinese expert consensus on the use of topical timolol maleate treatment of infantile hemangiomas].[Pubmed:28275803]
Shanghai Kou Qiang Yi Xue. 2016 Dec;25(6):744-747.
Non-selective beta-blocker propranolol has been proved by FDA as the first-line agent for infantile hemangioma (IH) with dramatic response. To reduce the side effects caused by systemic administration of propranolol, timolol maleate treatment has been increasingly used as an alternative to systemic beta-blockers and watchful waiting for many IH patients in recent years. However, the appropriate indications, drug dosage, dosing regimen, time for initiation, optimal duration, monitoring for side effects still remains controversial. To standardize the use of topical timolol in treating IH, avoid overtreatment or under-treatment, as well as minimize complications, a Chinese expert consensus on the use of topical timolol treatment of IH has been approved and written by a multidisciplinary experts group based on an up-to-date literature review and repeated discussion, which can be used to reduce inappropriate variations in clinical practice and to promote the delivery of high quality, evidence-based health care for IH patients.
Evaluation of the effects on choroidal thickness of bimatoprost 0.03% versus a brinzolamide 1.0%/timolol maleate 0.5% fixed combination.[Pubmed:28376651]
Cutan Ocul Toxicol. 2017 Dec;36(4):397-403.
OBJECTIVE: To investigate the effects of two different medical treatment options on choroidal thickness (CT) in cases of open-angle glaucoma (OAG). METHODS: Sixty-seven eyes newly diagnosed with OAG and 52 healthy eyes constituting the control group were included in the study. Glaucomatous eyes were randomly divided into two subgroups; Group I was started on bimatoprost 0.03% and Group II on a brinzolamide 1.0%/timolol maleate 0.5% fixed combination (BTFC). Intraocular pressure (IOP), ocular pulse amplitude (OPA) and subfoveal CT measurements were performed in all eyes in the study before treatment and on weeks 2, 4 and 8 after treatment. RESULTS: Mean initial IOP values in groups I and II and the control group were 25.5 +/- 4.7, 25.1 +/- 5.2 and 16.1 +/- 2.9 mmHg, mean OPA values were 3.7 +/- 1, 3.6 +/- 1.4 and 2.4 +/- 0.6 mmHg and mean CT values were 269.4 +/- 83, 264.5 +/- 84.4 and 320.1 +/- 56.6 mum, respectively. Eight weeks after treatment, mean IOP values in Groups I and II and the control group were 18.3 +/- 2.6, 18.1 +/- 3.4 and 15.7 +/- 2.9 mmHg, mean OPA values were 2.9 +/- 1.2, 2.8 +/- 1.5 and 2.3 +/- 0.8 mmHg and mean CT values were 290.2 +/- 87.3, 271.8 +/- 82.5 and 319.3 +/- 56.8 mum, respectively. No significant difference was determined in terms of the decrease in IOP and OPA obtained after treatment in Group I and Group II. However, a significant difference was observed between the two groups in terms of choroidal thickening after treatment. CONCLUSION: The use of topical ocular hypotensive medication in eyes with OAG results in an increase in CT. This increase is relatively greater with bimatoprost 0.03% therapy compared to BTFC.
Synthesis and optical resolution of (R)- and (S)-trans-7-Hydroxy-2-[N-propyl-N-(3'-iodo-2'-propenyl)amino]tetralin: a new D3 dopamine receptor ligand.[Pubmed:8277513]
J Med Chem. 1993 Dec 24;36(26):4308-12.
An improved method for synthesis and resolution of (R,S)-trans-7-hydroxy-2-[N-propyl-N-(3'-iodo-2'-propenyl)amino]tetralin (trans-7-OH-PlPAT,5), a new D3 dopamine receptor ligand, was reported. Both isomers, (R)-(+)- and (S)-(-)-5, were prepared and characterized. HPLC retention times obtained on a chiral column for these isomers were consistent with those observed for [125I]-(R)-(+)- and (S)-(-)-5. Direct radioiodination of an optically resolved tin precursor, (R)-(+)-7, yielded the desired [125I](R)-(+)-5, which is a simpler method for synthesis of this ligand. Binding studies with membrane preparations containing D3 dopamine receptors expressed in Spodoptera frugiperda (Sf9) cells also suggested that the [125I](R)-(+)-5 is the active isomer (Kd = 0.05 nM). The schemes described may provide an efficient way for synthesizing a large quantity of this new D3 dopamine receptor ligand for in vivo behavior studies.
In vitro binding of a novel dopamine D3 receptor ligand: [125I]trans-7-OH-PIPAT-A.[Pubmed:8519278]
Eur J Pharmacol. 1993 Apr 22;235(1):165-6.
An iodinated dopamine D3 receptor ligand, [125I]trans-7-OH-PIPAT-A-trans-7-hydroxy-2-(N-n-propyl-N-3'-iodo-2 '- propenyl)aminotetralin, was developed. This ligand demonstrated unique high affinity and selectivity toward the dopamine D3 receptor; Kd = 0.48 nM and Bmax = 240 fmol/mg of protein in rat striatal membrane homogenates.